Growth Dynamics following Growth hormone treatment in group of Iraqi patients with Turner’s Syndrome

Abstract

Background: Short stature is a well-known consequence of Turner’s syndrome (TS) and treatment with growth hormone can be improved the height of those patients, determination of the growth hormone velocity dynamics can help us to predict the optimum period for growth hormone treatment response. Objective: To study growth dynamics, which explained by height standard deviation, growth velocity and growth velocity standard deviation subsequent to growth hormone treatment in patients with Turner’s syndrome. Patient and Methods: During the period from January 2010 to January 2020, medical records of (30) patients with Turner’s syndrome (TS) were registered for this study, treated with growth hormone (GH). Where growth hormone (GH) dose was 0.06 IU/kg/day. Patients' height, mid-parental height (MPH), Bone age, the target height, the height standard deviation value, growth velocity and growth velocity standard deviation value were measured during Periodic follow-up of the patients every (3) months. Growth dynamics that explained by growth velocity, growth velocity Standard deviation and height standard deviation were compared before and after finishing treatment. Results: The average of height at beginning of treatment was 1.04±0.49 and the average of height at end of treatment is 1.3±0.154. While the difference in average is significant p=0.002. The difference between average of height standard deviation value at beginning of treatment and the average of height standard deviation value at end of treatment is also significant p =0.001. The first 2 years had the highest growth velocity and after that the growth velocity almost steady the same. The first year had lowest growth velocity standard deviation and the last year had the highest growth velocity standard deviation. There was no side effects observed was observed during treatment protocol. Conclusion: The growth velocity dynamics peak was more encountered during the first two years of treatment making it the optimum period of interest for compliance with growth hormone treatment.